Vanda Pharma Files 8-K for 'Other Events' on Feb 5, 2024
Ticker: VNDA · Form: 8-K · Filed: Feb 5, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-action, regulatory-filing, other-events
TL;DR
**VNDA filed an 8-K for 'Other Events' on Feb 5, 2024, signaling new, undisclosed info.**
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on February 5, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing indicates that the company is likely disclosing information that doesn't fit neatly into other specific 8-K categories but is still deemed important enough to be reported to the SEC. For investors, this matters because it signals that Vanda Pharmaceuticals is providing new, potentially significant information that could influence their perception of the company's financial health or operational status, even if the specific details aren't yet public.
Why It Matters
This filing signals that Vanda Pharmaceuticals is disclosing new, potentially material information to the public, which could impact investor sentiment and stock valuation.
Risk Assessment
Risk Level: medium — The 'Other Events' category can sometimes hide significant news, making the specific impact unknown until further details are released.
Analyst Insight
A smart investor would monitor Vanda Pharmaceuticals Inc. for subsequent filings or press releases that provide specific details about the 'Other Events' mentioned in this 8-K, as the current filing lacks specific actionable information.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — the registrant filing the 8-K
- February 5, 2024 (date) — the date of the earliest event reported and the filing date
- 001-34186 (other) — Commission File No. for Vanda Pharmaceuticals Inc.
- VNDA (other) — trading symbol for Vanda Pharmaceuticals Inc.
- The Nasdaq Global Market (other) — exchange where Vanda Pharmaceuticals Inc. common stock is registered
FAQ
What is the primary purpose of Vanda Pharmaceuticals Inc.'s 8-K filing dated February 5, 2024?
The primary purpose of Vanda Pharmaceuticals Inc.'s 8-K filing dated February 5, 2024, is to report 'Other Events' and 'Financial Statements and Exhibits' as per Item Information in the filing.
What is the trading symbol and the exchange where Vanda Pharmaceuticals Inc.'s common stock is registered?
Vanda Pharmaceuticals Inc.'s common stock trades under the symbol 'VNDA' and is registered on 'The Nasdaq Global Market', as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.
What is the business address and phone number of Vanda Pharmaceuticals Inc. as listed in the filing?
The business address of Vanda Pharmaceuticals Inc. is '2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037' and their telephone number is '(202) 734-3400', according to the 'BUSINESS ADDRESS' section.
What is the state of incorporation for Vanda Pharmaceuticals Inc.?
Vanda Pharmaceuticals Inc. is incorporated in 'Delaware', as indicated in the 'State or other jurisdiction of incorporation' section of the filing.
What is the Central Index Key (CIK) for Vanda Pharmaceuticals Inc.?
The Central Index Key (CIK) for Vanda Pharmaceuticals Inc. is '0001347178', as found in the 'FILER: COMPANY DATA' section of the filing.
Filing Stats: 459 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-02-05 16:34:05
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Ma
Filing Documents
- d772316d8k.htm (8-K) — 25KB
- d772316dex991.htm (EX-99.1) — 6KB
- g772316g0205143923554.jpg (GRAPHIC) — 4KB
- 0001193125-24-024112.txt ( ) — 158KB
- vnda-20240205.xsd (EX-101.SCH) — 3KB
- vnda-20240205_lab.xml (EX-101.LAB) — 18KB
- vnda-20240205_pre.xml (EX-101.PRE) — 11KB
- d772316d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated February 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 5, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary